Clinical Pain Research

Katarina Eklund*, Britt-Marie Stålnacke, Gunilla Stenberg, Paul Enthoven, Björn Gerdle and Klas-Göran Sahlén

A cost-utility analysis of multimodal pain rehabilitation in primary healthcare

Objectives: Multimodal rehabilitation programs (MMRPs) have been shown to be both cost-effective and an effective method for managing chronic pain in specialist care. However, while the vast majority of patients are treated in primary healthcare, MMRPs are rarely practiced in these settings. Limited time and resources for everyday activities alongside the complexity of chronic pain makes the management of chronic pain challenging in primary healthcare and the focus is on unimodal treatment. In order to increase the use of MMRPs incentives such as cost savings and improved health status in the patient group are needed. The aim of this study was to evaluate the cost-effectiveness of MMRPs for patients with chronic pain in primary healthcare in two Swedish regions. The aim of this study was to evaluate the cost-effectiveness of MMRPs at one-year follow-up in comparison with care as usual for patients with chronic pain in primary healthcare in two Swedish regions.

Methods: A cost-utility analysis was performed alongside a prospective cohort study comparing the MMRP with the alternative of continuing with care as usual. The health-related quality of life (HRQoL), using EQ5D, and working situation of 234 participants were assessed at baseline and one-year follow-up. The primary outcome was cost per quality-adjusted life year (QALY) gained while the secondary outcome was sickness absence. An extrapolation of costs was performed based on previous long-term studies in order to evaluate the effects of the MMRP over a five-year time period.

Results: The mean (SD) EQ5D index, which measures HRQoL, increased significantly (p<0.001) from 0.34 (0.32) to 0.44 (0.32) at one-year follow-up. Sickness absence decreased by 15%. The cost-utility analysis showed a cost per QALY gained of 18 704 € at one-year follow-up.

Conclusions: The results indicate that the MMRP significantly improves the HRQoL of the participants and is a cost-effective treatment for patients with chronic pain in primary healthcare when a newly suggested cost-effectiveness threshold of 19 734 € is implemented. The extrapolation indicates that considerable cost savings in terms of reduced loss of production and gained QALYs may be generated if the effects of the MMRP are maintained beyond one-year follow-up. The study demonstrates potential benefits of MMRPs in primary healthcare for both the patient with chronic pain and the society as a whole. The cost-effectiveness of MMRPs in primary healthcare has scarcely been studied and further long-term studies are needed in these settings.

Keywords: chronic pain; cost-utility analysis; multimodal rehabilitation; primary healthcare; sickness absence.

Introduction

Chronic non-malignant pain, defined as a persistent or recurrent pain that lasts more than three months [1, 2], is a major public health challenge that causes both individual suffering and inflicts a heavy economic burden on society.
A large survey of chronic pain in Europe showed that nearly 20% of adult Europeans suffer from moderate to severe chronic pain that affects their social and working lives considerably [5]. One out of three patients in Swedish primary healthcare seeks care due to pain and of these, almost 40% suffer from chronic pain [6]. Similarly, a cross-national study found that 22% of primary healthcare patients had chronic pain and that the odds of work disability are doubled for these patients compared with those not affected by chronic pain [7]. In Sweden, chronic pain is one of the most common reasons for long-term sickness absence [8] leading to considerable costs in terms of loss of production. Moreover, chronic pain is associated with increased healthcare consumption [4, 8–10]. In 2003, the Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) estimated that the costs for chronic pain of at least moderate intensity amounted to 87.5 billion SEK of which around 90% accounted for costs due to loss of production [8].

Multimodal rehabilitation is a team-based intervention with a biopsychosocial approach that has been developed to address the widespread impact of chronic pain on the physical, mental and social condition of the patient [11, 12]. Multimodal rehabilitation programs (MMRPs) have been shown to be more effective for reducing pain and disability than care as usual [8, 11, 13, 14]. MMRPs have also been shown to reduce sickness absence [15–17]. Systematic reviews have demonstrated the cost-effectiveness of MMRPs in specialist care [18, 19].

MMRPs have primarily been offered in specialist care for patients with complex chronic pain. The launch of the national rehabilitation warranty by the Swedish government in 2009 [20] made it possible for patients with less complex chronic pain to access MMRPs in primary healthcare settings with the help of economic compensation. The aim of the rehabilitation warranty was to reduce sickness absence and support return to work by offering access to evidence-based rehabilitation as an early intervention for persons suffering from chronic musculoskeletal pain. The effectiveness of MMRPs explicitly in primary healthcare has scarcely been studied. A few studies have shown that MMRPs for patients with chronic pain contributed to increased work capacity and decreased healthcare consumption [21–24]. One of them, a long-term study, also showed that MMRPs have positive effects on pain intensity, functional impairment and quality of life [21].

Limited time and resources alongside the complexity of pain conditions makes the assessment and management of chronic pain in primary healthcare challenging [25–27]. MMRPs have high initial costs in terms of time and resources [11], which may be one of the reasons for the intervention being under-utilized in primary healthcare [27, 28]. Considering that the vast majority of patients with chronic pain are treated at primary healthcare level, there is a need for more research on the economic consequences of MMRPs in these settings [24, 26, 29, 30]. Hence, the aim of this study was to evaluate the cost-effectiveness of multimodal rehabilitation programs for patients with chronic pain compared with care as usual in primary healthcare.

Methods

Design

This was a prospective cohort study of patients attending MMRPs in primary healthcare in two Swedish regions. The observations were at baseline, after termination of the MMRP and after one year. In the study, we compared the effects of the MMRP with the alternative of continuing with care as usual. A cost-utility analysis was executed, the focus being on the health-economic effects of MMRPs. The study covered the MMRPs financed by the rehabilitation warranty between the years 2012 and 2015 when the primary healthcare centers received financial compensation for the MMRP.

Participants and setting

Participants attended the MMRPs between August 29 2012 and December 16 2015. In total, 11 primary healthcare centers participated, five in the northern part of Sweden and six in the southern part. The participants were consecutively assessed and referred to participate in the MMRP before participation in the program. The inclusion criteria were 1) disabling chronic pain that had lasted more than three months, 2) age between 18 and 65 years, 3) no further medical assessments needed, 4) sufficient knowledge of the Swedish language, 5) agreements not to participate in other parallel treatments. The exclusion criteria were 1) ongoing major somatic or psychiatric disease, 2) a history of significant substance abuse and 3) state of acute crisis.

General aims of the MMRP are to enhance the daily and emotional function and quality of life of the patient as well as to promote return to work [1]. The MMRPs included physical exercises and activities, relaxation, coping strategies and pain education. The program lasted over a period of 6–10 weeks with 1½–3½ h/week during office hours. In most cases, the sessions were held at the local primary healthcare center of the patient, thus the majority of the patients were able to avoid long-distance travel. Most sessions were group interventions or a combination of group intervention and individual activity. The multi-professional MMRP teams differed between primary healthcare centers but always included a physiotherapist and an occupational therapist. At least one of them was trained in cognitive behavioral therapy, since that is a key element of the MMRP [31]. The team members were offered a two-day training course on team work, chronic pain and consequences related to living with this condition. There is an array of unimodal chronic pain treatments such as pharmaceutical, surgical, neuro-augmentative, somatic, behavioral,
rehabilitative, complementary and alternative treatment [8, 32, 33]. Nevertheless, MMRP with its biopsychosocial approach to the complexity of chronic pain has the strongest evidence and is therefore the first-line recommendation in Swedish healthcare [33].

Procedure and questionnaires

Data were gathered from participating primary healthcare centers using a comprehensive questionnaire with patient-reported outcome measures (PROM) combined with standardized instruments from the Swedish Quality Registry for Pain Rehabilitation (SQRP) (www.ucr.uu.se/nrs/) and a number of additional variables in order to adapt the questionnaire to primary healthcare settings. The instruments included were the numeric pain rating scale (NPRS) [34], the hospital anxiety and depression scale (HADS) [35], the functional rating index (FRI) [36], the chronic pain acceptance questionnaire (CPAQ) [37], the pain catastrophizing scale (PCS) [38], two variables from the life satisfaction questionnaire (LiSat-11) [39], the European quality of life instrument (EQ5D-3L) [40] and one item from the work ability index (WAI) [41]. The questionnaire was filled in by the patient before assessment, immediately after MMRP and one year later.

The outcome measures of the questionnaire were chosen in accordance with recommended core outcome domains by the initiative on methods, measurement, and pain assessment in clinical trials: IMMpACT recommendations [42]. At the end of 2015, the data from the primary healthcare centers were gathered into one common registry which in turn was connected to the SQRP. The SQRP has evaluated the effects of MMRPs at specialist clinics since 1998. The primary healthcare version was named the Swedish Quality Registry for Pain Rehabilitation for primary healthcare (SQRP-PC).

In the present study, data at baseline and one-year follow-up were evaluated with a focus on the EQ5D descriptive system and self-reported sickness absence according to the percentages used by the Swedish Social Insurance Agency (25, 50, 75 or 100%). The EQ5D is a generic preference-based instrument developed by the EuroQol group. It consists of two parts: a descriptive part which measures health-related quality of life (HRQoL) on five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and the EQVAS, a visual analogue scale that generates a self-rating HRQoL. When the dimensions from the descriptive system are combined, a utility score or EQ5D index between 0 and 1 is generated (1=full health and 0=worst imaginable health state/death). The EQ5D index reflects the health status of the individual at the measured time point [40].

Outcome measures

The primary outcome measure was cost per gained quality-adjusted life year (QALY) measured using EQ5D. The secondary outcome measure was sickness absence at one-year follow-up compared with baseline.

Economic evaluation

Continuously rising healthcare expenditure and restricted budgets makes it more difficult to prioritize and make choices in healthcare [63]. Information about the cost-effectiveness of a treatment can support decision-makers in allocating limited healthcare resources fairly and to achieve maximum value [40, 44]. The purpose of an economic evaluation is to compare two or more alternative courses of action considering both costs and consequences [44, 45]. According to Torrance [45], the comparative intervention can sometimes be whatever would have happened in the absence of the intervention being considered. In this study, the results of the patients who were enrolled for MMRP were compared with the baseline data for the same patient group, as if they would have continued receiving care as usual without participation in the MMRP. In so doing, we assumed that the average mean of the EQ5D index and working situation would remain unchanged without participation in the MMRP. Care as usual was standard medical treatment offered by the primary healthcare center, e.g. pharmacological treatment or unimodal treatment by physiotherapist or occupational therapist. The economic evaluation consisted of a cost-utility analysis (CUA) with cost per QALY gained as outcome [44]. The economic evaluation is described according to the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement [66].

Cost data: The CUA was conducted from a partial societal perspective including costs for the intervention and costs in terms of loss of production due to sickness absence. The intervention costs were set as equal to the financial compensation that the primary healthcare centers received within the rehabilitation warranty, that was 25,000 SEK per patient treated.

The costs resulting from loss of production were evaluated by assuming that the contribution to overall production of an employee is equal to the cost of employing him or her, including wages plus additional costs incurred by the employer to employ the person, according to the human capital approach [44]. The average salary (all professional categories included) in Sweden 2012 was 29,800 SEK (in 2015, the average net salary was 32,000 SEK) and the general payroll tax 31.42% [47, 48]. The average yearly salary was 4,69,958 SEK (29,800*12*1.3142) and was interpreted as being equal to the annual cost of loss of production for a patient on full-time sickness absence. Other healthcare costs, other sector costs, and costs for the patient and families were not included because they were assumed not to differ between the two alternatives being compared. Drummond et al. [44] argue that costs common to the two options being compared can be excluded as they would not affect the choice between the two alternatives. Costs derived from sickness benefits were not included since they, from a societal perspective, are considered to be an income transfer from those who work to those who are on sick leave, thus they do not change the aggregated resources of the society [49]. Costs are presented in Swedish crowns (SEK) (1 SEK=0.09397 EUR [50]). No discounting of costs was made in the cost calculations since the follow-up was only one year.

Cost-utility: QALY is the most commonly used utility value in CUA [43]. The advantages with QALY as a measure of health gain are that it incorporates both reduced morbidity (quality gains) and reduced mortality (quantity gains) in one single measure. QALY also allows a comparison of economic evaluations across different healthcare areas and is widely used as a decision-making foundation for prioritizing scarce resources [44]. One QALY is defined as a year of full or "optimal" health. The QALY gain is the difference in utility score between two or more measurement points multiplied by the time (in years) spent in the particular health state. The results of the CUA are presented as the incremental cost-utility ratio (ICUR) which is the ratio of the incremental cost and the incremental QALY. The ICUR stands for
the additional cost per QALY gained associated with the new intervention in comparison with treatment as usual or alternative treatment [43].

**Extrapolation of costs:** The CUA presents a one-off benefit with the time horizon applied in the economic evaluation, which in this study was one year after treatment. The MMRP aim to make permanent changes in the patients’ ability to both cope with and understand their pain and to enhance participation in work and social life. Taking this into consideration a period of one year may not be long enough to capture the major health and economic consequences of MMRP. One way to evaluate the effectiveness of an intervention over a longer time period is to extrapolate the effects by implementing results from previous long-term studies in the same field [21, 51, 52]. The extrapolation serves as a way of addressing the unavoidable uncertainty about expected costs and effects when assessing cost-effectiveness [64]. A discount rate of 3.5% was applied in the extrapolation in accordance with the recommendation of Drummond et al. that the rate should be between 3 and 5% [44].

**Cost-effectiveness threshold:** The cost-effectiveness threshold for one gained QALY was set at 2,10,000 SEK or 19,734 € which is a newly advocated estimation based on the work of Claxton et al. on behalf of The National Institute of Health and Care Excellence (NICE) [53, 54]. This cost-effectiveness threshold is based on a marginal productivity approach, where the threshold is a measure of the opportunity cost in terms of the health produced by the least cost-effective intervention that the new intervention will replace [53]. Thus, theoretically, in a healthcare system with a fixed budget, an intervention with a cost per QALY below the given threshold is favorable [63].

**Statistical analysis**

The data analysis was conducted according to the per protocol principle, accounting for those persons who filled out the questionnaire both at baseline and at one-year follow-up. The analyses were carried out with IBM SPSS version 24.0 (Chicago, IL) with the significance level set at p<0.05 (two-tailed) and 95% confidence intervals (CI). Data were first summarized and examined with the help of descriptive statistics. A comparison within groups was carried out at baseline and one-year follow-up using a parametric paired sample t-test. No imputation was used for missing values. Cohen’s d effect size (ES) was calculated with the help of a psychometric webpage [55]. Absolute ES of 0.0–0.2 was interpreted as non-significant, 0.2–0.69 as small, 0.5–0.79 as medium, and ≥0.8 as large [56].

**Results**

In total, 503 patients were examined for participation (Figure 1). Of these, 31 patients did not fulfill the inclusion criteria and were thereby excluded from the study. Five patients declined to fill in the questionnaire and were not included. Another 39 patients did not complete the MMRP and 194 did not fill in the questionnaire at one-year follow-up, which left in total 234 patients for further analysis. The only significant differences in baseline characteristics between those who did and did not complete MMRP were that the patients who completed the program had a higher educational level and those who completed the one-year

| Table 1: Baseline descriptive data of the participants in the multimodal rehabilitation program. Continuous variables are given as mean and standard deviation (SD) and categorical variables as numbers and percentages (%) |
|---------------------------------------------------------------|
| **Sex** | **All patients** | **Women** | **Men** |
| Small | 234 | 200 | 34 |
| Age, years | 43.6 (10.8) | 43.5 (10.7) | 44.7 (11.7) |
| Country of origin | | | |
| Sweden | 206 (88.0) | 177 (88.5) | 29 (85.3) |
| Other country | 28 (12.0) | 23 (11.5) | 5 (14.7) |
| Education | | | |
| Compulsory school | 40 (17.4) | 33 (16.5) | 7 (20.6) |
| Upper secondary school | 141 (61.3) | 119 (59.5) | 22 (64.7) |
| University/College | 45 (19.6) | 40 (20.0) | 5 (14.7) |
| Pain location variation | | | |
| Constant | 180 (76.9) | 152 (77.9) | 28 (90.3) |
| Varies | 46 (19.7) | 43 (22.1) | 3 (9.7) |
| Pain duration, years | 9.8 (9.1) | 8.9 (9.6) | 10.0 (9.0) |
| Pain intensity last week | 6.5 (1.8) | 6.5 (1.8) | 6.7 (1.5) |
| Current pain intensity | 6.0 (2.0) | 6.0 (2.0) | 6.0 (1.9) |
| Number of pain sites | 14.6 (8.1) | 15.2 (8.4) | 11.3 (6.5) |
| Anxiety, HADS ≥11 | 93 (40.3) | 83 (41.9) | 10 (30.3) |
| Depression, HADS ≥11 | 42 (18.3) | 38 (19.2) | 4 (12.5) |
| Self-reported work ability | 3.7 (2.7) | 3.7 (2.9) | 3.7 (2.7) |
| FRI | 57.8 (16.1) | 57.3 (16.4) | 60.8 (13.9) |
| CPAQ-AE | 29.0 (11.4) | 29.2 (11.5) | 28.1 (10.8) |
| CPAQ-PW | 23.4 (8.8) | 23.4 (8.8) | 23.6 (9.3) |
| Pain catastrophizing scale | 23.3 (10.7) | 23.5 (10.9) | 20.5 (10.1) |
| LiSat-life | 3.63 (1.33) | 3.63 (1.35) | 3.62 (1.23) |
| LiSat-vocation | 2.94 (1.50) | 2.92 (1.48) | 3.09 (1.64) |
| Health-related quality of life | | | |
| EQ5D index | 0.34 (0.32) | 0.34 (0.32) | 0.30 (0.30) |
| EQ VAS | 46.1 (19.3) | 46.4 (19.5) | 44.4 (18.4) |

1The hospital anxiety and depression scale (HADS).
2The functional rating index (FRI).
3The chronic pain acceptance questionnaire (CPAQ), activity engagement (AE), and pain willingness (PW).
4The life satisfaction questionnaire (LiSat-11).
5The European quality of life instrument contains the EQSD descriptive system and a visual analogue scale.
follow-up scored two points lower on the pain catastrophizing scale.

Hence, 234 participants were included in the study. Table 1 illustrates the baseline characteristics of the study participants. The variation in pain duration was large: between 12 and 480 months (40 years). The median (interquartile range, IQR) pain duration was 72 months (six years). An examination of quartiles showed that less than 5% had a pain duration of more than 351 months (29.25 years) and 25% more than 180 months (15 years). Half of the participants had a pain duration under 75 months (6.25 years).

Sickness absence

A 15% reduction in sickness absence was seen at one-year follow-up (Table 2). Both the group of participants on part-time and on full-time sickness absence decreased with 17 and 12% respectively. Two of the participants had retired at follow-up (marked as missing in Table 2). The net reduction of sickness absence corresponded to 11.25 full-time employments, including sickness absence due to disability pension. The disability pension rate (full-time or part-time) was 8.6% at baseline and 11.2% at one-year follow-up (Table 3).

Loss of production

The annual cost of loss of production for a person on full-time sickness absence was estimated to be 4,69,058 SEK (see Cost data in methods section). As demonstrated in Table 4 the costs resulting from loss of production was the heaviest cost item in the cost calculation for the different treatment options compared. Gains in terms of reduced loss of production attributable to return to work were estimated using a previous Swedish study on return to work after multi-professional rehabilitation by Kärholm et al. [57]. In the study, it was shown that the effect on return to work after rehabilitation occurred during the second six-month period after the end of the intervention, seen in a one-year follow-up [57]. Applying these results, we assumed that those who reported being full-time or part-time at work at one-year follow-up had returned to work nine months after baseline. In other words, the length of time back at work was three months during the follow-up period. It was not possible to determine at which point in time the return to work took place based on the data analyzed in this study.

Cost-utility analysis

There was a statistically significant increase in the mean (SD) EQ5D index (p<0.001) from 0.34 (0.32) to 0.44 (0.32). Similarly, the EQ VAS score increased significantly (Table 5).

The QALY gain was calculated using the area under the curve (AUC) method and the trapezium rule [43, 58]. The AUC in the present study consisted of the area T1 representing the time between baseline and after treatment and T2 corresponding to the time from after treatment to one-year follow-up (Figure 2). For n + 1 measurements yi at time

| Table 3: Disability pension amongst the participants. |
|---------------------------------|-----------------|-----------------|
|                                 | Baseline (%)    | One-year follow-up (%) | Difference |
| Full-time (100%)                | 4 (1.9)         | 6 (2.9)           | +2 |
| Part-time (75%)                 | 1 (0.5)         | 1 (0.5)           | 0  |
| Part-time (50%)                 | 9 (4.3)         | 14 (6.8)          | +5 |
| Part-time (25%)                 | 4 (1.9)         | 2 (1.0)           | −2 |
| Total                           | 18 (8.6)        | 23 (11.2)         | +5 |

*The total amount of sickness absence at baseline was equal to 81 full-time employments.
The QALY gain was 0.097 QALYs per patient, which corresponds to about 1.2 months or 35 days of spared life time in perfect health for each patient or 22.75 QALYs gained for all the 234 participants. The incremental costs were 45,28,243 SEK and the incremental QALY gains 22.75 QALYs per patient or 22.75 QALYs correspond to about 1.2 months or 35 days of spared life time.

**Long-term costs and effects**

To estimate future costs and effects of MMRPs, we extrapolated our results using results from previous long-term studies described below (Table 6). There were not enough studies to make an extrapolation based solely on studies originating from primary healthcare, hence specialist care was also included. The extrapolation comprised three studies on the long-term effects of MMRPs. In the study by Rivano-Fischer et al. [51], the effects on sick-leave after MMRPs were evaluated and a long-term reduction of sick leave was shown. In the study, the number of patients not on sick leave increased from baseline (34%) to one-year follow-up and continued to increase (63%) at two-year follow-up. In a study by Norrefalk et al. [52] where work-related interdisciplinary rehabilitation was evaluated for long-term pain, findings showed that 49% of the 63% of patients who had returned to work at one-year follow-up were still working after three years. In a five-year follow-up on early MMRP for patients with musculoskeletal pain and disability by Westman et al. [21], the authors found that the group of patients that had gone from full-time sick leave to part-time or full-time work dropped from 81% at one-year to 58% at five-year follow-up. We could not find a study with a four-year follow-up. Therefore, we estimated an increase in sickness absence as a mean of the increased percentage at three-year and five-year follow-up. All percentages of decrease/increase were calculated in relation to one-year follow-up.

We could only find one study reporting long-term effects on HRQoL after an MMRP in primary healthcare. Westman et al. (2006) studied the quality of life after early multimodal rehabilitation for patients with musculoskeletal pain and disability and could see significant improvements at five-year follow-up [21]. If we apply these results and assume that the HRQoL of the participants persists at the level of one-year follow-up, an extrapolation with a five-year perspective would generate 121 QALYs gained for all 234 participants and an ICUR of 37,424 SEK or 3,517 €. If we, in turn, assumed that the HRQoL would decrease by half during a five-year period,

**Figure 1:** Flow-chart.

**Figure 2:** Calculations of quality-adjusted life year (QALY) gain using the trapezium rule. * The time point “after MMRP” is the average intervention duration of eight weeks (56 days or approximately 0.156 years).
the ICUR would amount to 50,325 SEK or 4,729 €. The extrapolated ICURs are ¼–⅓ of the ICUR at one-year follow-up which is explained by the high initial costs of MMRPs that burden the costs of year one and part of year two after MMRPs. Independently of which of these assumptions is implemented, MMRP must be considered cost-effective. The extrapolation of cost savings demonstrated that the total cumulative discounted value of the MMRPs amount to around one million euros after five years (Table 6).

### Discussion

The aim of this study was to evaluate the cost-effectiveness of MMRPs in Swedish primary healthcare in the light of the heavy socio-economic burden inflicted by chronic pain. The cost-effectiveness was evaluated from a partial societal perspective. The CUA demonstrated an ICUR of 18,704 € at one-year follow-up which indicates that MMRPs within the rehabilitation warranty were cost-effective compared with care as usual when implementing a common cost-effectiveness threshold of 19,734 € [53, 54]. The HRQoL of the participants increased significantly. The number of patients not on sickness absence increased by 15% and contributed to cost savings in terms of reduced loss of production. The results of our CUA were in line with the only CUA found in earlier research by Whitehurst et al. [22].

They showed that stratified primary healthcare management was cost-effective for low back pain patients at high risk of persistent disability compared with care as usual. In addition, the authors found that the intervention reduced work absence and improved quality of life. According to a study by Lang et al. [59], multidisciplinary rehabilitation for chronic low back pain in primary healthcare improved HRQoL significantly compared with care as usual, which is also in line with our results. In addition, Lang et al., together with a number of studies on multidisciplinary rehabilitation for chronic pain patients in primary healthcare settings, conclude that the intervention increases work capacity [21, 23, 24].

Two recently published papers concerning the effects of MMRP on pain-related sickness absence in Sweden and within the rehabilitation warranty presented differing results. Busch et al. [60] compared participants of MMRPs with matched controls and found that MMRPs were not effective in reducing sickness absence compared with care as usual. MMRP was, nevertheless, effective in reducing the risk of future disability pension. Rivano Fischer et al. [51] found that MMRPs had a favorable effect on sick leave patterns for the participants. There are a few notable differences between these two studies and our study. Busch et al. [60] included patients at two different time periods at both specialist and primary healthcare from the last quarter of 2009 until the end of 2010 and retrieved data from the Swedish Social Insurance Agency. Rivano Fischer et al. [51] included data from specialist care reported to the SQRP during 2007–2011 supplemented with sickness absence data from the Swedish Social Insurance Agency. Busch et al. [60] and Rivano Fischer et al. [51] included data on a national level. The present study was based on data gathered during the second half of 2012 to the end of 2015 and was restricted to primary healthcare in two Swedish regions. Our results are in agreement with the results of Rivano Fischer and al [51]. A shared feature was that the studies included more recent data than the study by Busch et al. [60]. The more positive results in terms of sickness absence may be related to the fact that the units offering MMRP within the rehabilitation warranty had gained more experience and had evolved associated

| Follow-up | Intervention cost | Cost savings (reduced productivity loss) | Cumulative cost savings | Total cumulative discounted value (discount rate 3.5%) |
|-----------|-------------------|------------------------------------------|-------------------------|-----------------------------------------------|
| One-year  | (234* 25 000) 0 850 000 | [11.25*469 958* (3/12)] 1 321 757 | 1 321 757 | -4 528 243 |
| Two-year  | 0 | (14.51*469 958)* 6 820 266 | 8 142 023 | 2 139 628 (2 292 023/1.035*) |
| Three-year | 0 | (9.675*469 958)* 4 546 844 | 12 688 867 | 6 030 814 (6 686 472/1.035*) |
| Four-year | 0 | (9.225*469 958)* 4 335 363 | 17 024 230 | 9 033 524 (10 366 177/1.035*) |
| Five-year | 0 | (8.6625*469 958)* 4 071 011 | 21 095 241 | 11 033 667 (13 104 535/1.035*) |

*11.25 full-time employment gained, 4,69,958 SEK yearly salary, three months of return to work.
*A 29 % (63–34%) decrease in sickness absence at two-year-follow-up; 11.25*1.29=13.2 employments.
*A 14% (63–49%) increase in sickness absence at three-year-follow-up; 11.25*0.86=9.675 employments.
*A 18% (13% + 23%)/2 increase in sickness absence at four-year-follow-up; 11.25*0.82=9.225 employments.
*A 23% (81–58%) increase in sickness absence at five-year-follow-up; 11.25*0.77=8.6625 employments.
routines. Nevertheless, the phase of implementation of MMRPs was still ongoing in the two county councils when the data for the present study were gathered.

When healthcare policy makers decide how limited resources should be used in order to maximize health outcomes, the focus should, according to Drummond et al. [44], rather be on the predicted health benefits and costs offered by the intervention than on the traditional rules of statistical significance. Our study demonstrates that even small improvements in sickness absence contribute to large economic savings in the long term. In addition to these financial aspects, the observed increase in the HRQoL score indicated that MMRP also improve the health status of the patient. These gains are important, bearing in mind the severe clinical condition of the patients illustrated by Table 1 and that the patients constitute a selection of patients that have already tried various unimodal treatments with no manifest improvements in their condition. These findings are reinforced by a recent study [61] based on the same data as the present study from SQRP-PC as well as the yearly report from the SQRP-PC [62]. Both conclude that MMRPs in primary healthcare contribute to significant improvements in pain, function, daily activity and HRQoL.

**Future directions**

Little research has been done on the cost-effectiveness of MMRP in primary healthcare and problems of methodological heterogeneity make it difficult to draw conclusions from the results [30]. There is a need for consensus and standardization of the MMRPs and how the effectiveness of MMRP can be measured. This applies not only when it comes to the selection of participants, team set-up and program content but also regarding the design of the economic evaluation, the perspective, the time-horizon and how costs are valued [23, 30]. Another challenge is the implementation of MMRP in primary healthcare which will require considerable investments in both time and effort from an already tightly scheduled primary healthcare personnel [25, 31] in terms of reorganization and changing ways of working and thinking. To argue for such changes, it is necessary to demonstrate the health benefits and cost savings of MMRP for the healthcare sector, the patient and society with a focus on long-term evaluations.

**Strengths and limitations**

Our study contributes new and valuable insights regarding research on MMRPs in primary healthcare. One of the strengths of this study is its execution in real-life clinical settings with regular primary healthcare staff. The study was carried out on a cross-national level, representing both the north and south parts of Sweden, which enhances the generalizability of the results. The costs and cost savings in the economic evaluation as well as the extrapolation were calculated from the lower bottom limit. There are other studies with more optimistic findings. For example, the study by Busch et al. published in 2011 [63] reports a tendency of decrease in sick leave of at least three years after inclusion in multidisciplinary chronic pain interventions. In the study, the improvements in all-cause sickness absence decline slowly but benefits still exist at 10-year follow-up, at which point sickness absence had not yet reached baseline levels. The calculations in the current study are presented with transparency in order to make it easy for the reader to understand and follow how the results were reached.

It is important to point out the methodological limitations of the study when drawing conclusions from the results. This was a prospective cohort study where detailed information about costs and intervention content could not be retrieved. The study design was adapted to these circumstances and we were unable to complete a CUA with competing alternatives, as is recommended in health economic literature. Therefore, we could not present the relative effectiveness of MMRPs and the CUA in itself cannot be used to support decision-making concerning resource allocation.

Randomized controlled studies (RCT) are often called for to minimize bias and strengthen the empirical evidence in an economic evaluation [64]. Our design and access to data did not allow us to perform an RCT which can be regarded as a limitation. Moreover, we have made several assumptions which imply that the results should be regarded with caution. We assumed that the average mean of the EQ5D measurements and working situation of the participants would remain unchanged without participation in the MMRP. In addition, the intervention costs were set as equal to the financial compensation to primary healthcare centers, which might be a reason for both under- and overestimation. The extrapolation relies on assumptions based on results from prior long-term studies and should also be regarded with care. The generalizability of the results is reduced due to the low response rate at follow-up. An explanation for this can be that the MMRP as an intervention was new for the primary healthcare centers and the professionals lacked experience of a structured follow-up of patients. The non-response analysis showed that the participants who did not fulfill the MMRPs had a lower educational level and scored two points lower on the
pain catastrophizing scale. We cannot rule out that the participants who experienced less satisfactory effects after MMRP did not feel motivated to answer the follow-up questionnaire.

Conclusions

In conclusion, our study shows that MMRP is a cost-effective intervention for treating patients with chronic pain in primary healthcare. Considerable societal cost savings and improved health-related quality of life may be generated if the effects of the multimodal rehabilitation program are maintained beyond one-year follow-up. If the decrease in sickness absence continued for another 10 months after one-year follow-up, the intervention costs for all studied participants would be balanced by cost savings due to reduced loss of production. After that, the additional cost savings generated would be a pure economic gain for the society. Our results may serve as a platform for further discussion on the socioeconomic implications of MMRP in primary healthcare and as incentive for future and more profound research in these settings.

Data security and management

The authors had full access to all the data in the study and had final responsibility for the decision to submit for publication. All personal data collected are stored in accordance with applicable regulatory requirements. Data are stored securely to maintain confidentiality. To preserve participant anonymity, only allocated trial numbers are recorded on trial documentation or computer software except for the consent form and contact details. Documents with identifiable information are stored separately to other study documents.

Data availability statement

The datasets generated and/or analyzed in this study are not publicly available as the Ethical Review Board has not approved the public availability of these data.

Research funding: This study was supported by grants from the Swedish Research Council, the County Councils of Östergötland and Västerbotten (forsknings-ALF) and the Swedish Association for Survivors of Polio, Accident and Injury (RTP). The sponsors of the study had no role in the study design, data collection, data analysis, data interpretation, writing of the report, or the decision to submit for publication.

Author contributions: All authors listed qualify for authorship and have participated sufficiently in the work to take public responsibility for appropriate portions of the content. KE takes responsibility for the integrity of the work as a whole, from inception to published article. KE analyzed the data, BMS, GS, PE, BG, and KGS have contributed substantially to conception and design. All authors have contributed to the interpretation of data, revising it critically for important intellectual content and approval of the final version to be published.

Informed consent: Written informed consent was obtained from all individuals included in this study.

Ethical approval: The Research Ethics Committee at Umeå University has approved the present study (Dnr 2017-438-32M).

Conflict of interest: The authors have no known conflicts of interest to declare.

References

1. Gerdle B, Stålnacke BM, Söderlund A, Äsenlöf P. Indikation för multimodal rehabilitering vid långvarig smärta. 2011, Contract No: 2011: 02. Available from: https://skr.se/download/18.49299951664200d714c71b1/1403715504788/SK%20Indikation_%C3%B6r_multimodal_rehabilitering%20slut.pdf.
2. Treede RD, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, et al. A classification of chronic pain for ICD-11. Pain 2015;156:1003–7.
3. Gatchel RJ. The continuing and growing epidemic of chronic low back pain. Healthcare 2015;3:838–45.
4. Manchikanti L, Singh V, Datta S, Cohen SP, Hirsch JA. Comprehensive review of epidemiology, scope, and impact of spinal pain. Pain Physician 2009;12:835–70.
5. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006;10:287–333.
6. Hasselström J, Liu-Palmgren J, Råsjö-Wrååk G. Prevalence of pain in general practice. Eur J Pain 2002;6:375–85.
7. Gureje O, Von Korff M, Simon GE, Gater R. Persistent pain and well-being: a World Health Organization study in primary care. JAMA 1998;280:147–51.
8. Swedish Council on Health Technology. SBU systematic review summaries. Methods of treating chronic pain: a systematic review. Stockholm: Swedish Council on Health Technology Assessment (SBU). Copyright (c) 2006 by the Swedish Council on Health Technology Assessment; 2006 [In Swedish: Statens beredning för medicinsk och social utvärdering (SBU)].
9. Becker A, Held H, Redaelli M, Strauch K, Chenot JF, Leonhardt C, et al. Low back pain in primary care: costs of care and prediction of future health care utilization. Spine 2010;35:1714–20.
10. Blyth FM, March LM, Brnabic AJ, Cousins MJ. Chronic pain and frequent use of health care. Pain 2004;111:51–8.
11. Kamper SJ, Apeldoorn AT, Chiarotto A, Smeets RJ, Ostelo RW, Guzman J, et al. Multidisciplinary biopsychosocial rehabilitation for chronic low back pain: cochrane systematic review and meta-analysis. BMJ 2015;350:h444.

12. Gatchel RJ, Peng YB, Peters ML, Fuchs PN, Turk DC. The biopsychosocial approach to chronic pain: scientific advances and future directions. Psychol Bull 2007;133:581–624.

13. Sscascighini L, Toma V, Dober-Spielmann S, Sprott H. Multidisciplinary treatment for chronic pain: a systematic review of interventions and outcomes. Rheumatology 2008;47:670–8.

14. Guzman J, Esmaiil R, Karjalainen K, Malimavaara A, Irvin E, Bombardier C. Multidisciplinary rehabilitation for chronic low back pain: systematic review. BMJ 2001;322:1511–6.

15. Jensen IB, Busch H, Bodin L, Hagberg J, Nygren A, Bergstrom G. Cost effectiveness of two rehabilitation programmes for neck and back pain patients: a seven year follow-up. Pain 2009;142:202–8.

16. Norlund A, Ropponen A, Alexanderson K. Multidisciplinary interventions: review of studies of return to work after rehabilitation for low back pain. J Rehabil Med 2009;41:115–21.

17. Norrefalk JR, Ekholm K, Linder J, Borg K, Ekholm J. Evaluation of a multiprofessional rehabilitation programme for persistent musculoskeletal-related pain: economic benefits of return to work. J Rehabil Med 2008;40:15–22.

18. Lin CW, Haas M, Maher CG, Machado LA, van Tulder MW. Cost-effectiveness of guideline-endorsed treatments for low back pain: a systematic review. Eur Spine J 2011;20:1024–38.

19. Gatchel RJ, Okifuji A. Evidence-based scientific data documenting the treatment and cost-effectiveness of comprehensive pain programs for chronic nonmalignant pain. J Pain 2006;7:779–93.

20. Swedish Association of Local Authorities and Regions (SALAR). Multidisciplinary rehabilitation program in primary health care. Disabil Rehabil 2015;37:3518–26.

21. Westman A, Linton SJ, Theorell T, Ohrvik J, Wahlen P, Stenberg G. Evaluating the cost of implementing stratiﬁed primary care management for low back pain: a prospective, population-based, sequential comparison study. Spine 2015;40:514–20.

22. Whitehurst DG, Bryan S, Lewis M, Hay EM, Mullis R, Foster NE. Implementing stratiﬁed primary care management for low back pain: cost-utility analysis alongside a prospective, population-based, sequential comparison study. Spine 2015;40:405–14.

23. Stein KF, Miculescu A. Effectiveness of multidisciplinary rehabilitation treatment for patients with chronic pain in a primary health care unit. Scand J Pain 2013;4:190–7.

24. Westman A, Linton SJ, Ohrvik J, Wahlen P, Theorell T, Leppert J. Controlled 3-year follow-up of a multidisciplinary pain rehabilitation program in primary health care. Disabil Rehabil 2010;32:307–16.

25. Stanos S, Brodsky M, Argoff C, Clauw DJ, D’Arcy Y, Donevan S, et al. Rethinking chronic pain in a primary care setting. Postgrad Med 2016;128:502–15.

26. Mills S, Torrance N, Smith BH. Identification and management of chronic pain in primary care: a review. Curr Psychiatry Rep 2016;18:22.

27. Peterson K, Anderson J, Bourne D, Mackey K, Helfand M. Effectiveness of models used to deliver multimodal care for chronic musculoskeletal pain: a rapid evidence review. J Gen Intern Med 2018;33:71–81.

28. Rogerson MD, Gatchel RJ, Biener SM. A cost utility analysis of interdisciplinary early intervention versus treatment as usual for high-risk acute low back pain patients. Pain Pract 2010;10:382–95.

29. Smith BH, Torrance N. Management of chronic pain in primary care. Curr Opin Support Palliat Care 2011;5:137–42.

30. Becker A. Health economics of interdisciplinary rehabilitation for chronic pain: does it support or invalidate the outcomes research of these programs?. Curr Pain Headache Rep 2012;16:127–32.

31. Stenberg G, Pietila Holmmer E, Stalnacke BM, Enthoven P. Healthcare professional experiences with patients who participate in multimodal pain rehabilitation in primary care—a qualitative study. Disabil Rehabil 2016;38:2085–94.

32. Turk DC, Wilson HD, Cahana A. Treatment of chronic non-cancer pain. Lancet 2011;377:2226–35.

33. Swedish Council on Health Technology. SBU systematic review summaries. rehabilitation of patients with chronic pain conditions: a systematic review. Stockholm: Swedish Council on Health Technology Assessment (SBU). Copyright (c) 2010 by the Swedish Council on Health Technology Assessment; 2010 [In Swedish: Statens beredning för medicinsk och social utvärdering (SBU)].

34. Boonstra AM, Stewart RE, Koke AJ, Oosterwijk RJ, Swaan JL, Schreurs KM, et al. Cut-off points for mild, moderate, and severe pain on the numeric rating scale for pain in patients with chronic musculoskeletal pain: variability and influence of sex and catastrophizing. Front Psychol 2016;7:1466.

35. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361–70.

36. Seife RJ, Menke JM. Functional rating index: a new valid and reliable instrument to measure the magnitude of clinical change in spinal conditions. Spine 2001;26:78–87.

37. McCracken LM, Vowles KE, Eccleston C. Acceptance of chronic pain: component analysis and a revised assessment method. Pain 2004;107:159–66.

38. Sullivan MJL, Bishop SR, Pivik J. The pain catastrophizing scale: development and validation. Psychol Assess 1995;7:524–32.

39. Fugl-Meyer AR, Melin R, Fugl-Meyer KS. Life satisfaction in 18- to 64-year-old Swedes: in relation to gender, age, partner and immigrant status. J Rehabil Med 2002;34:239–44.

40. Szende A, Oppe M, Devlin NJ. EQ-5D value sets: inventory, comparative review, and user guide. Dordrecht: Springer; 2007.

41. Alavinia SM, de Boer AG, van Duijnbooden JC, Frings-Dresen MH, Burdorf A. Determinants of work ability and its predictive value for disability. Occup Med 2009;59:32–7.

42. Taylor AM, Phillips K, Patel KV, Turk DC, Dworkin RH, Beaton D, et al. Assessment of physical function and participation in chronic pain clinical trials: IMMPACT/OMERACT recommendations. Pain 2016;157:3836–50.

43. Brazier J. Oxford medicine online. In: Catcliffe J, Saloman J, Tsuchiya A, editors. Measuring and valuing health benefits for economic evaluation, 2 ed. Oxford: Oxford University Press; 2016.

44. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes, 4th ed. Oxford: Oxford University Press; 2015, vol. xiii:445 p.
45. Torrance GW. Preferences for health outcomes and cost-utility analysis. Am J Manag Care 1997;3:8–20.

46. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. BMJ 2013;11:6.

47. Statistics Sweden. [In Swedish: Statistiska centralbyrån (SCB)]. Löneutveckling 1992–2017. Available from: https://www.scb.se/hitta-statistik/statistik-efter-amne/arbetsmarknad/loner-och-arbetskostnader/lonestructurstatistik-hela-ekonomin/pong/tabell-och-diagram/loneutveckling/ [updated 19 Jun 2018; cited 14 Mar 2019].

48. The Swedish Tax Agency. Belopp och procent–inkomstår 2012. 2012. [In Swedish: Skatteverket]. Available from: https://www.skatteverket.se/privat/skatteverket/beloppochprocent/ [cited 14 Mar 2019].

49. Neumann PJ, editor. Cost-effectiveness in health and medicine, 2nd ed. New York, NY: Oxford University Press; 2016.

50. European Central Bank. Eurosystem. ECB euro reference exchange rate: Swedish krona (SEK). Available from: https://www.ecb.europa.eu/stats/policy_and_exchange_rates/euro_reference_exchange_rates/html/eurofxref-graph-sek.en.html [cited 16 Jun 2019].

51. Fischer M, Persson EB, Stalnacke BM, Schult ML, Lofgren M. Return to work after interdisciplinary pain rehabilitation: one- and two-year follow-up based on the Swedish Quality Registry for Pain rehabilitation. J Rehabil Med 2019;51:281–9.

52. Norrefalk JR, Ekholm J, Borg K. Ethnic background does not influence outcome for return-to-work in work-related interdisciplinary rehabilitation for long-term pain: 1- and 3-year follow-up. J Rehabil Med 2006;38:87–92.

53. Henriksson MSJ, Johannesen K, Eriksson T. Tröskelvärden och kostnadeffektivitet - innebörde och implicatiorer för ekonomiska utvärderingar och beslutsfattande i hälso- och sjukvården. Linköping: Linköping universitet: Institutionen för medicin och hälsa, (CMT) Cfuamt; 2018, Report No.: Rapport 2018:3.

54. Claxton K, Martin S, Soares M, Rice N, Spackman E, Hind s et al. Methods for the estimation of the national Institute for health and care excellence cost-effectiveness threshold. Health Technol Assess 2015;19:1–503.

55. Lenhard WLA. Calculation of effect sizes 2016. Available from: https://www.psychometrica.de/effect_size.html [cited 16 Jun 2019].

56. Cohen J. Statistical power analysis for the behavioral sciences. Hillsdale: L. Erlbaum Associates; 1988.

57. Kärholm J, Ekholm K, Jakobsson B, Ekholm J, Bergroth A, Schüldt K. Effects on work resumption of a co-operation project in vocational rehabilitation. Systematic, multi-professional, client-centred and solution-oriented co-operation. Disabil Rehabil 2006;28:457–67.

58. Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ 1990;300:230–5.

59. Lang E, Liebig K, Kastner S, Neundorfer B, Heuschmann P. Multidisciplinary rehabilitation versus usual care for chronic low back pain in the community: effects on quality of life. Spine J 2003;3:270–6.

60. Busch H, Bramberg EB, Hagberg J, Bodin L, Jensen I. The effects of multimodal rehabilitation on pain-related sickness absence—an observational study. Disabil Rehabil 2018;40:1646–53.

61. Pietila-Holmner E, Enthoven P, Gerdle B, Molander P, Stalnacke BM. Long-term outcomes of multimodal rehabilitation in primary care for patients with chronic pain. J Rehabil Med 2020;52: jrm00023.

62. Swedish Quality Registry for Pain Rehabilitation (SQRP). [In Swedish: Nationella registret över smärtsrehabilitering (NRS)]. Primärvård Smärtsrehabilitering. 2019, Rapport 2019:1. Årsrapport 2018 NRS primärvård. Avslutade patienter 2018. Available from: https://www.ucr.uu.se/nrs/nrs-primaervard/arsrapporter-primarvard [cited 27 Nov 2019].

63. Busch H, Bodin L, Bergstrom G, Jensen IB. Patterns of sickness absence a decade after pain-related multidisciplinary rehabilitation. Pain 2011;152:1727–33.

64. Hariton E, Locascio JJ. Randomised controlled trials—the gold standard for effectiveness research: study design: randomised controlled trials. BJOG 2018;125:1716.